- The disease
- Diabetic kidney disease (DKD) is a complication of diabetes in which persistently high blood sugar damages the kidneys over time, reducing their ability to filter waste from the blood. In people with type 1 diabetes, DKD is a leading cause of end-stage kidney failure requiring dialysis or transplant. The condition is typically detected through urine protein tests (albuminuria) and estimated kidney filtration rate measurements, but these markers do not reliably identify all patients at early risk. Earlier or more accurate identification of patients at high risk of progression is an active area of research.
- What the asset is trying to do
- PromarkerD is a blood-based diagnostic test, not a therapeutic drug. It analyses a panel of proteins in a blood sample to generate a risk score intended to identify type 1 diabetes patients at elevated risk of developing or progressing DKD before standard clinical markers detect a problem. The approach differs from existing screening methods, which rely primarily on urine albumin levels and kidney filtration estimates, by using a proteomic (protein measurement) signature from plasma. The specific protein targets and algorithm underpinning the score are .
- What the trial is measuring, and why it matters
- The Phase 2 program is evaluating the diagnostic performance of PromarkerD, assessing how accurately the test identifies patients who go on to develop or worsen DKD compared with standard clinical markers. Key measures in diagnostic studies typically include sensitivity (ability to detect true cases), specificity (ability to correctly exclude non-cases), and area under the receiver operating characteristic curve (AUC-ROC), which summarises overall discrimination. The precise primary and secondary endpoints for this study are .
- Efficacy benchmarks in this setting
- In the type 1 DKD setting, standard clinical markers include urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). Published studies assessing conventional albuminuria-based screening report sensitivity and specificity figures that vary considerably by threshold and population; specific benchmark figures for this exact study population and design are and should be sourced from peer-reviewed literature before comparison. Because PromarkerD is in an early study phase and no head-to-head data against approved diagnostic methods in this exact population are publicly available from the input provided, any figures from this study would not be statistically comparable to results from larger, independently validated cohorts.